Friday, July 10, 2026

pharma · H Pylori Infection · H. Pylori Infection · PHAT

Phathom Pharmaceuticals

Phathom Pharmaceuticals is a pharma organization headquartered in Florham Park, USA. It trades on NYSE under ticker PHAT. Primary therapeutic focus areas include H Pylori Infection, H. Pylori Infection, Eosinophilic Esop

100 Campus Drive, Suite 102, Florham Park, New Jersey 07932, US HQ
2018 Founded
420 Employees
Public company Type
PHAT · NYSE Ticker
Company details
Status
Public
HQ
100 Campus Drive, Suite 102, Florham Park, New Jersey 07932, US
Founded
2018
Employees
420
Programs
11
Drugs
5
Patents
8
Clinical program

Vonoprazan

Phase 1 · small molecule · Gastroesophageal Reflux

Vonoprazan for Gastroesophageal Reflux is a Phase 1 program (small_molecule) at Phathom Pharmaceuticals with 1 ClinicalTrials.gov record(s).

← All Phathom Pharmaceuticals projects Phase 1 small molecule completed

Internal code VPED-102

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Phathom Pharmaceuticals
Phase
Phase 1
Modality
small_molecule
Indication
Gastroesophageal Reflux
Status
completed
Trials
1